Persistence of Infliximab in Circulation for 7 Years?
Department of Pathology and.
Sarah M
SM
Kelting
Division of Rheumatology, Department of Medicine, University of Virginia School of Medicine and Health Sciences Center, Charlottesville, VA.
Donald L
DL
Kimpel
Department of Pathology and dbruns@virginia.edu.
David E
DE
Bruns
D000068879:Adalimumab / Q000097:blood / Q000276:immunology / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000097:blood* / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab / Q000097:blood* / Q000276:immunology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D013167:Spondylitis, Ankylosing / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab